UCB

Tweet this page
<
2015
2016
2017
2018
2019
2020
2021
2022
2023
>
Registration as it was on 02 Mar 2023
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

200,000€ - 299,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

0.75 Fte (2)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    UCB

    EU Transparency Register

    294359117093-66 First registered on 24 Apr 2015

    Goals / Remit

    UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 700 people in 36 countries, the company generated revenue of € 5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

    Main EU files targeted

    Any health, pharmaceutical and/or life sciences policy stemming from the European institutions, especially in relation to EU Pharmaceutical, Industrial, IP, Research, Digital and Trade strategies.

    This includes initiatives related to Antimicrobial resistance (AMR), ATMP Regulation, Brexit, Clinical Trials, Data Protection, AI and Data Strategies, EU industrial policy, EU IP policy incl. SPCs, EU Relative Efficacy Assessment, EU research policy, EU trade policy, Healthcare Systems, HTA & Market Access, EU research programs such as IMI and Horizon Europe, Medical Devices, Orphan Medicinal Products and Paediatric Regulations, Patient access to innovation, Patient safety, Pharmaceuticals in the environment, Sustainability & Sustainable Development Goals.

    Address

    Head Office
    Allée de la Recherche 60
    Brussels 1070
    BELGIUM
    EU Office
    Allée de la Recherche 60
    Brussels 1070
    BELGIUM

    Website

    http://www.ucb.com

  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    50%1
    25%1

    Lobbyists (Full time equivalent)

    0.75

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    1 FTE (50%)
    1 FTE (25%)

    People with less than 10% of their time spent on activities covered by the Register are not reported

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    EFPIA = European Federation of Pharmaceutical Industries and Associations
    (http://efpia.eu/)

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    200,000€ - 299,999€

    Major contributions in closed year

    TypeNameAmount
    Grant Horizon 2020 87,472€

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    200,000€ - 299,999€

    Other financial info

    EU Grants:
    1. INSPIRE-Innovation in Safety Pharmacology for Integrated cardiovascular safety assessment to Reduce adverse events and late stage drug attrition INSPIRE MSCA-ITN-2019 MARIE SKLODOWSKA-CURIE INNOVATIVE TRAINING NETWORKS HORIZON 2020


    2. SeizeIT II - Seizure detection Seize IT II 19263 EIT - Health HORIZON 2020

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard